Add like
Add dislike
Add to saved papers

Chronic Myeloid Leukemia Developing After Successful Treatment of Acute Promyelocytic Leukemia.

Acute promyelocytic leukemia (APL) has been regarded as a highly curable disease. Therapy-related leukemia is one of the important late complications that affect long-term survival rates in APL patients. Therapy-related acute myeloid leukemia and myelodysplastic syndrome are the major forms of therapy-related leukemias. We report a rare event of chronic myeloid leukemia (CML) that developed after successful treatment of APL with all-trans-retinoic acid in combination with chemotherapy. Rather unexpectedly, CML developed 7 years after APL. Cytogenetic and molecular studies proved the independence of these two entities. It was found that CML progressed rapidly after a short-term response to a combination therapy with hydroxyurea, interferon-α and arsenic trioxide. We propose that optimization of chemotherapy regimen and treatment intensity may reduce the risk of developing a secondary leukemia, while long-term monitoring cytogenetics of APL patients after treatment may help determine the development of a secondary leukemia at early stage.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app